Supplementation reduces mortality: vitamin D and a healthy diet for cancer patients

Initial Note: This article was previously published and has been updated according to scientific and informative criteria. Its purpose is informational and does not replace medical advice. For therapeutic or supplementation choices, consult your doctor.

IN BRIEF

• Meta-analyses of clinical trials suggest a possible reduction in cancer mortality associated with regular vitamin D supplementation; the effect is not uniform across all studies and depends on dose, frequency, and population.
• Randomized studies do not show a consistent reduction in overall cancer incidence, while some analyses find reductions in cancer-specific mortality. [1][2]
• The mode of administration (daily intake vs. bolus) and participant profile (age, nutritional status, BMI) can modify the observed effect. [2][5][6]
• Among trials on single tumor types, some data suggest benefits in specific contexts (e.g., colorectal cancer in treated patients), but confirmation from larger, longer-term studies is needed. [4][7]

Abstract: what does science say?

Vitamin D is a secosteroid with known roles in bone metabolism and increasing attention for immune and anti-inflammatory functions. Recent clinical evidence indicates that vitamin D supplementation may not consistently reduce the overall incidence of cancer in the general population, but some meta-analyses of randomized trials show a decrease in cancer mortality when supplementation is taken regularly. Several analyses highlight that the frequency of administration (e.g., daily doses rather than large intermittent doses) and participant characteristics partly determine the variability of results. Plausible mechanisms include modulation of innate and adaptive immunity, anti-inflammatory effects, and regulation of cell proliferation; however, most clinical evidence is still heterogeneous and does not allow for definitive conclusions on preventive or therapeutic efficacy. [Synthesis not cited: this section is written as an editorial summary of available evidence].

MAIN SECTION

1. Status of clinical evidence: trials and meta-analyses

In recent years, several meta-analyses and large randomized trials have been published exploring the effect of vitamin D supplementation on cancer incidence and mortality. An updated meta-analysis of RCTs found a significant reduction in total cancer mortality associated with vitamin D supplementation, but without showing a reduction in the total incidence of new cancers [1]. An individual-patient-data (IPD) analysis and systematic review confirmed that, at an aggregate level, the effect on mortality is modest and not always statistically significant in the primary analysis, but it clearly emerges in subgroups that received regular daily doses rather than high intermittent doses [2].

The large VITAL trial, which evaluated 2000 IU/day for approximately 5 years in middle-aged and older adults, did not show a clear reduction in overall cancer incidence but contributed to data on mortality and subgroup analyses that inform subsequent meta-analyses [3]. Other trials with monthly or bolus administration schemes (ViDA, D-Health) yielded heterogeneous results, suggesting that the frequency of administration may be a crucial element in translating biological effects into clinical outcomes [5][6].

2. Effect size and variability

Estimates derived from meta-analyses indicate reductions in cancer mortality in the order of 10–15% in some trial aggregations, but with confidence intervals that sometimes include the absence of effect. Differences between studies arise from: dosages used, follow-up duration, average age of participants, baseline 25(OH)D status in the blood, co-supplementation with calcium, mode (daily vs. bolus), and adherence. Some statistical synthesis works (sequential analyses) believe that the evidence is sufficient to support a relative reduction in cancer-specific mortality, but not to state an effect on primary cancer prevention in the general population [5].

Plausible mechanisms: anti-inflammatory, immunomodulatory, and cellular actions

Plausible biological mechanisms

Vitamin D acts through the vitamin D receptor (VDR), present in many cells, including immune cells and tumor tissues. At the biological level, effects on proliferation, cell differentiation, apoptosis, and inflammatory pathways (e.g., NF-κB modulation) are recognized. These mechanisms make a role plausible in modulating tumor progression or the body's ability to respond to the onset of neoplastic cells, especially in tissues where local vitamin D metabolism is active.

Interaction with the immune system

Vitamin D can enhance some components of innate immunity (e.g., the antimicrobial peptide cathelicidin) and modulate the adaptive response, with anti-inflammatory effects that theoretically can reduce pro-tumor microenvironments. However, immunological modulation is complex: in some phases, it can promote controlled pro-inflammatory responses, in others, it can promote more tolerant phenotypes. This complexity limits the direct interpretation between serum levels and clinical outcomes.

PRACTICAL SECTION

What it means in practice

For patients and the general public, current evidence does not support simple claims such as "vitamin D prevents all cancers" or "administering vitamin D always reduces the risk of cancer death." However, summaries of randomized trials suggest that regular vitamin D supplementation may be associated with a modestly consistent reduction in cancer mortality in some populations, especially with daily regimens and in older individuals. [1][2][5]

This translates into some practical considerations: 1) check vitamin D status through your doctor (serum 25-OH-D dosage) when indicated; 2) discuss with your doctor if and how to supplement, taking into account clinical conditions, medication intake, and other vitamins/minerals; 3) prefer supplementation methods and dosages established by your doctor rather than experimenting with large uncontrolled boluses; 4) remember that a healthy diet, physical activity, and specific screenings remain the main preventive and supportive measures for cancer patients.

KEY POINTS TO REMEMBER

• Vitamin D supplementation is not a proven cancer therapy, but some trials show a reduction in cancer mortality in specific contexts. [1][2]
• The observed effect is more consistent with regular (daily) intake compared to large intermittent doses. [2][5]
• There is no robust evidence that vitamin D reduces the overall incidence of cancer in the general population. [1][5]
• Assess vitamin status with your doctor before starting supplementation and do not replace cancer therapies with supplements. [3][4]
• Clinical decisions must be individualized: age, comorbidities, BMI, and baseline 25(OH)D levels influence the response. [2][6]

LIMITATIONS OF EVIDENCE

Difference between observational studies and causal evidence

Much of the associations between serum vitamin D levels and cancer risk or prognosis come from observational studies, which can document correlations but do not prove causality. The most robust evidence for causality comes from randomized trials; even these often have limitations in design, duration, dose, and population. It is essential to distinguish correlation (e.g., low 25(OH)D levels associated with worse prognosis) from proof that supplementation changes the clinical course.

Methodological limitations and variability

Differences between trials include: dose and form of vitamin D (D2 vs D3), frequency of administration (daily vs bolus), duration of follow-up, adherence measures, populations with different prevalence of initial deficiency, and concomitant calcium use. Some studies have shown different effects in subgroups by age or BMI, suggesting that the effect is not universal. Furthermore, the outcome 'cancer incidence' often requires longer periods to manifest than the duration of many trials.

Editorial conclusion

Research on vitamin D and cancer has advanced: numerous RCTs and meta-analyses have provided useful but not yet conclusive data. Evidence suggests that regular vitamin D supplementation may modestly reduce cancer mortality in some contexts, while it does not appear effective in consistently reducing the overall incidence of neoplasms. The prudent approach for the public is based on individual clinical evaluation, correction of deficiency when present, and use of supplementation regimens agreed upon with the doctor. Consolidated preventive measures remain a priority: healthy lifestyles, screening, and evidence-based cancer therapies.

Editorial note

This update was drafted using institutional language and a review of the main meta-analyses and randomized trials available at the time of the update. The article aims to provide a transparent and evidence-based summary, maintaining accessible language for the general public. It does not replace individual clinical advice.

SCIENTIFIC RESEARCH

1. Keum N, Lee DH, Greenwood DC, et al. Vitamin D supplementation and total cancer incidence and mortality: a meta-analysis of randomized controlled trials. Ann Oncol. 2019;30(5):733-743. https://doi.org/10.1093/annonc/mdz059
2. Efficacy of vitamin D3 supplementation on cancer mortality: Systematic review and individual patient data meta-analysis of randomised controlled trials. Ageing Res Rev. 2023;101923. https://doi.org/10.1016/j.arr.2023.101923
3. Manson JE, Cook NR, Lee I-M, et al.; VITAL Research Group. Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. N Engl J Med. 2019;380(1):33-44. https://doi.org/10.1056/NEJMoa1809944
4. Ng K, Meyerhardt JA, Chan AT, et al. Effect of High‑Dose vs Standard‑Dose Vitamin D3 Supplementation on Progression‑Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer: The SUNSHINE Randomized Clinical Trial. JAMA. 2019;321(14):1370-1379. https://doi.org/10.1001/jama.2019.2402
5. Niu M, Zhang X, et al. Association between vitamin D supplementation and cancer incidence and mortality: a trial sequential meta-analysis of randomized controlled trials. Crit Rev Food Sci Nutr. 2022; (see DOI). https://doi.org/10.1080/10408398.2022.2056574
6. Moncrieff et al.; The D-Health Trial group. The D-Health Trial: a randomised controlled trial of the effect of vitamin D on mortality. Lancet Diabetes Endocrinol. 2022; (see DOI). https://doi.org/10.1016/S2213-8587(21)00345-4
The ViDA Study investigators. Effect of monthly high‑dose vitamin D supplementation on falls and non‑vertebral fractures: secondary and post‑hoc outcomes from the ViDA trial. Lancet Diabetes Endocrinol. 2017; (see DOI). https://doi.org/10.1016/S2213-8587(17)30103-1
7. Vaughan‑Shaw PG, et al. The effect of vitamin D supplementation on survival in patients with colorectal cancer: systematic review and meta‑analysis of randomised controlled trials. Br J Cancer. 2020;123:1705–1712. https://doi.org/10.1038/s41416-020-01060-8